# Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer

> **NCT01171755** · PHASE2 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Gemcitabine TS-1

## Key facts

- **NCT ID:** NCT01171755
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The objective response rate by more than two people are confirmed.
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171755, "Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01171755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*